{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:30Z","timestamp":1793885730929,"version":"4.8.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.07.011","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:48:49Z","timestamp":1784332129000},"page":"1508.e1-1508.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-3245","authenticated-orcid":false,"given":"Nihar","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8589-799X","authenticated-orcid":false,"given":"Gonzalo","family":"Bentolila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-6644","authenticated-orcid":false,"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2026.07.011_bib0001","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.011_bib0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ejh.14117","article-title":"Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data","volume":"112","author":"Pang","year":"2024","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.011_bib0003","article-title":"Real-world efficacy of extending duration of letermovir prophylaxis for allogeneic stem cell recipients","volume":"27","author":"Masuda","year":"2025","journal-title":"Transpl Infect Dis Off J Transplant Soc"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.011_bib0004","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1093\/cid\/ciaf646","article-title":"An analysis of cytomegalovirus-specific cell-mediated immunity in a phase 3, randomized, placebo-controlled trial of letermovir prophylaxis in cytomegalovirus-seropositive recipients of an allogeneic hematopoietic cell transplant","volume":"82","author":"Papanicolaou","year":"2026","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.011_bib0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.011_bib0006","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ejh.14258","article-title":"Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a single center experience","volume":"113","author":"Desai","year":"2024","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.011_bib0007","doi-asserted-by":"crossref","first-page":"105.e1","DOI":"10.1016\/j.jtct.2024.12.010","article-title":"Letermovir for prevention of recurrent cytomegalovirus in high-risk allogeneic hematopoietic cell transplantation recipients","volume":"31","author":"Han","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.011_bib0008","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/jmv.26462","article-title":"Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective","volume":"93","author":"Alsumali","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.jtct.2026.07.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105422","article-title":"Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing","volume":"207","author":"Chou","year":"2022","journal-title":"Antiviral Res"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.011_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtct.2025.06.025","article-title":"American Society for Transplantation and Cellular Therapy series #11: updated cytomegalovirus guidelines in hematopoietic cell transplant and cellular therapy recipients","volume":"31","author":"Khawaja","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.011_bib0011","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jtct.2026.07.011_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coviro.2021.11.013","article-title":"Epigenetic control of the Epstein-Barr lifecycle","volume":"52","author":"Guo","year":"2022","journal-title":"Curr Opin Virol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2026.100200","article-title":"Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease","volume":"3","author":"Weigel","year":"2026","journal-title":"Blood Neoplasia"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:20:35Z","timestamp":1793884835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726005683"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}